Search

everythinglearnresearchcommunity

for

Search:↓

A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.

The user has been using finasteride for almost two years but is considering switching to dutasteride and is curious about adding RU58841. They decide to stick with dutasteride due to concerns about RU58841's safety.

An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.

The conversation discusses using Minoxidil with Tretinoin and Fexofenadine for hair loss. Some users doubt its effectiveness, noting Fexofenadine's unproven results for androgenetic alopecia.

Mixing dutasteride capsules and tretinoin cream into liquid minoxidil is questioned for effectiveness. A user responds negatively.

The conversation discusses hair loss treatment progress over 7 months using Dutasteride, oral Minoxidil, and recently started RU58841. The last photo shows the progress made with these treatments.

The user has been using finasteride, minoxidil, and a derma stamp for hair loss for nearly three months and is considering adding tretinoin. They are advised to be patient, as results typically take 6-12 months, and are exploring other options like oral minoxidil and dutasteride.

Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.

Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

A user switched from finasteride to Avodart (dutasteride) due to the ineffectiveness and poor quality of finasteride in their country. They advise others in similar situations to seek original brands.

The user has been using finasteride for 3 years with good results and wants to switch to dutasteride combined with tamsulosin. They are seeking more information about tamsulosin.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Alfatradiol is suggested as another potential solution.

The user shared progress pictures over four months using topical finasteride, topical and oral minoxidil, topical RU58841 daily, and oral dutasteride once a week. The pictures are spaced about a month apart.

A user expressed concern about using low-dose topical finasteride while conceiving, but was reassured that the risk of affecting a fetus is negligible. The user stopped using finasteride during pregnancy and switched to minoxidil and ketoconazole, while others shared experiences and advice on using these treatments safely.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A user shared progress pictures showing hair regrowth after using a homemade oral solution of 1 mg dutasteride and 2.5 mg minoxidil. Commenters noted significant improvement and increased body hair.

Use tretinoin three times a week, dermaroll once a week, and apply minoxidil daily, but avoid using all three on the same day. Tretinoin is preferred over hydrocortisone and should not be used immediately after dermarolling.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.

A user is considering using compounded Minoxidil with Tretinoin from Medical Wellness Center to improve hair growth. They are also curious about the effects of higher Minoxidil doses and adding Tretinoin to their regimen.

The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.

The user switched from finasteride and topical minoxidil to oral dutasteride and minoxidil, with plans to add RU58841, to improve hair growth and address a stubborn bald spot. Despite initial shedding, the user noticed thicker, darker hair and plans to continue the treatment or consider a hair transplant.